The agency awarded grants across seven labs to develop custom genetic treatments, but officials warn that completely altering a patient’s fundamental biological code carries a significant margin of error.
The Advanced Research Projects Agency for Health (ARPA-H) announced $160 million in grants to seven laboratories on Tuesday to develop custom gene-editing drugs, though agency officials immediately cautioned that the initiative's ability to rewrite the foundational biological instructions of the human body remains strictly theoretical at this stage.
The initiative, which saw its rollout delayed by the recent transition between presidential administrations, aims to jump-start the creation of bespoke genetic cures for rare diseases. However, citing a recent JAMA paper on synthetic biology, the agency stressed that permanently altering a patient's DNA is currently only associated with molecular transformation, and does not necessarily prove causation of a cure.
While early in-vitro data suggests we can engineer customized enzymes to snip and replace defective genetic sequences, we must acknowledge the limitations of a small sample size when completely rebuilding someone from the cellular level up.
Gable added that the clinical success of bespoke genetic rewriting relies heavily on self-reported patient data, noting that individuals whose entire genome has been synthetically recoded may just be experiencing a temporary placebo effect. The protocol for the seven participating labs mandates rigorous double-blind testing to ensure that the custom gene editing is actively eradicating congenital illnesses, rather than merely acting as an unstudied risk factor for spontaneous cellular combustion.
At press time, the FDA had issued an interim guidance regarding the $160 million effort, recommending that any cohort undergoing comprehensive biological re-authoring avoid operating heavy machinery until further peer-reviewed studies can confirm what species they have become.